Invitrogen™ LILRB2 Polyclonal Antibody

Description

In direct ELISAs and Western blots, approximately35% cross-reactivity with recombinant human (rh) ILT2 is observed and 5% cross-reactivity with rhILT5 is observed. Reconstitute at 0.2 mg/mL in sterile PBS. Endoxin level is <0.10 EU per 1 μg of the antibody by the LAL method.

CD85d, also known as LILRB2 or ILT4, is a member of the immunoglobulin-like transcript (ILT), leukocyte Ig-like receptor (LIR), and monocyte Ig-like receptor (MIR) family. It is a 110 kDa single transmembrane receptor with three Ig-like domains and a long cytoplasmic domain containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). CD85d is expressed on monocytes, macrophages, and dendritic cells. The receptor binds to non-classical class I molecules such as HLA-G, -B, and G1. Upon ligand binding, the tyrosine phosphatase SHP-1 interacts with the ITIMs, transducing a negative signal that inhibits immune response stimulation. This interaction is thought to contribute to tolerance during fetal implantation and plays a role in controlling inflammatory responses and cytotoxicity, helping to focus the immune response and limit autoreactivity. CD85d is also involved in organ allograft rejection, with the levels of ILT3 and ILT4 on dendritic cells suggesting its role in this process. The LILRB2 gene, located in a gene cluster at chromosomal region 19q13.4, encodes multiple transcript variants with different isoforms, highlighting its complexity and importance in immune regulation.